What is HC Wainwright's Estimate for CADL FY2025 Earnings?

Candel Therapeutics, Inc. (NASDAQ:CADL - Free Report) - Stock analysts at HC Wainwright reduced their FY2025 earnings estimates for Candel Therapeutics in a research note issued on Wednesday, February 26th. HC Wainwright analyst V. Bernardino now forecasts that the company will earn ($1.39) per share for the year, down from their previous estimate of ($1.35). HC Wainwright currently has a "Buy" rating and a $19.00 price target on the stock. The consensus estimate for Candel Therapeutics' current full-year earnings is ($1.47) per share.

Several other equities analysts also recently commented on CADL. Bank of America assumed coverage on shares of Candel Therapeutics in a research note on Friday, February 7th. They issued a "buy" rating and a $15.00 price target on the stock. Citigroup began coverage on shares of Candel Therapeutics in a research report on Thursday, February 20th. They set a "buy" rating and a $25.00 price objective for the company. Finally, Canaccord Genuity Group upped their price objective on shares of Candel Therapeutics from $20.00 to $25.00 and gave the stock a "buy" rating in a research report on Wednesday, February 26th.

Candel Therapeutics Stock Performance

Shares of CADL stock traded down $1.07 on Friday, hitting $7.91. The company's stock had a trading volume of 1,153,741 shares, compared to its average volume of 1,352,076. The stock's 50 day moving average is $8.33 and its 200-day moving average is $6.79. Candel Therapeutics has a fifty-two week low of $1.34 and a fifty-two week high of $14.60. The company has a market capitalization of $256.89 million, a PE ratio of -4.57 and a beta of -1.25.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in CADL. FMR LLC bought a new position in shares of Candel Therapeutics in the third quarter worth about $46,000. MetLife Investment Management LLC bought a new position in shares of Candel Therapeutics in the third quarter worth about $87,000. Atom Investors LP bought a new position in shares of Candel Therapeutics in the third quarter worth about $103,000. State Street Corp increased its stake in shares of Candel Therapeutics by 4.1% in the third quarter. State Street Corp now owns 492,005 shares of the company's stock valued at $3,410,000 after buying an additional 19,207 shares during the period. Finally, Barclays PLC increased its stake in shares of Candel Therapeutics by 327.1% in the third quarter. Barclays PLC now owns 28,688 shares of the company's stock valued at $199,000 after buying an additional 21,971 shares during the period. Institutional investors own 13.93% of the company's stock.

Insider Buying and Selling

In other news, CTO Seshu Tyagarajan sold 14,322 shares of the stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $7.22, for a total value of $103,404.84. Following the completion of the transaction, the chief technology officer now owns 96,790 shares of the company's stock, valued at approximately $698,823.80. This represents a 12.89 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Paul B. Manning bought 1,250,000 shares of the company's stock in a transaction dated Monday, December 16th. The stock was bought at an average cost of $6.00 per share, with a total value of $7,500,000.00. Following the acquisition, the director now directly owns 1,303,752 shares of the company's stock, valued at approximately $7,822,512. The trade was a 2,325.49 % increase in their position. The disclosure for this purchase can be found here. Insiders sold 41,529 shares of company stock valued at $313,512 over the last quarter. 41.60% of the stock is owned by company insiders.

About Candel Therapeutics

Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.